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OBJECTIVE: To evaluate antithrombin III (AT), thrombin (Fragment 1+2 [F1+2] and thrombin-antithrombin [TAT]) generation
markers, as well as other coagulation parameters, such as prothrombin time, partial activated thromboplastin time, thrombin time,
fibrinogen, euglobulin lysis time, and platelet count, in postmenopausal women after hormonal therapy.
STUDY DESIGN: Forty-five patients who received either 0.625 mg/day unopposed oral conjugated equine estrogen (CEE),
0.625 mg/day oral CEE plus medroxyprogesterone acetate (MP), or 50 µg/day transdermal 17beta-estradiol plus MP, were included.
Tests were performed before (T0) and after 3 (T3), 6 (T6) and 12 (T12) months of treatment. AT was determined by an amidolytic
method, whereas F1+2 and TAT complex were measured by ELISA.
RESULTS: There was a significant reduction in the AT level of patients who received oral CEE plus MP at T3. There was no AT
reduction in patients taking either oral CEE alone or transdermal 17beta-estradiol plus MP. F1+2 increased in all patients, but it
reached statistical significance only in patients receiving transdermal 17beta-estradiol MP at T3.
CONCLUSIONS: The CEE associated with MP treatment may reduce AT levels, whereas unopposed CEE or transdermal 17beta-
estradiol plus MP does not change AT. These changes might not be clinically relevant in the general population; however, hormonal
replacement therapy may increase the risk of thrombosis in women with congenital or acquired thrombophilia.
KEY-WORDS: Antithrombin III. Postmenopausal hormonal therapy. Estrogen. Menopause. Thromboembolism. Thrombin
generation.
INTRODUCTION
Traditionally, the blood coagulation scheme has been
divided into extrinsic and intrinsic pathways, converging
at the point where factor X is activated. The intrinsic path-
way (partial activated thromboplastin time) may be initi-
ated in vitro by the activation of factor XII, while the ex-
trinsic pathway (prothrombin time) is activated by the tis-
sue factor. However, such a division is mainly an artifact
of in vitro testing, and in vivo, there are interconnections
between the two pathways. For example, a tissue factor of
the extrinsic pathway, factor VIIa complex, also activates
factor IX in the intrinsic pathway. The coagulation cascade
activation determines the increase in activation of thrombin.
In turn, thrombin converts circulating soluble fibrinogen
into insoluble fibrin, resulting in local fibrin deposition and
induction of further platelet recruitment and aggregation
to form a hemostatic plug. In addition to catalyzing the fi-
nal steps of the coagulation cascade, thrombin also exerts
a variety of effects on the local vasculature and inflamma-
tion. It even actively participates in limiting the extent of
the hemostatic process. Once activated, the coagulation cas-
cade must be restricted to the local site of vascular injury
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to prevent clotting of the entire vascular tree. Besides re-
stricting factor activation to sites of exposed phospholipids,
clotting is also regulated by three types of natural antico-
agulants—proteins C and S, tissue factor pathway inhibi-
tor, and antithrombin III—that inhibit the activity of
thrombin and other serine proteases.1
Besides inducing coagulation, activation of the clotting
cascade also sets into motion a fibrinolytic cascade that lim-
its the size of the final clot. This is primarily accomplished
by the generation of plasmin, which breaks down fibrin and
interferes with its polymerization. The resulting fibrin split
products can also act as weak anticoagulants, and their el-
evated levels are helpful in diagnosing abnormal thrombotic
states, such as deep venous thrombosis. There are several
clot lysis tests available to assess the presence of increased
fibrinolysis in the clinical situation. The euglobulin lysis
test is actually a modified plasma clot lysis time, which
detects increased plasminogen activation and subsequent
fibrinolysis.2 It is important to emphasize that a disturbance
in normal hemostasis may result in thrombosis.2
Hormone therapy (HT) in postmenopausal women mini-
mizes the risk of osteoporosis and promotes relief of many
climacteric symptoms.3 Several case-control studies dem-
onstrated an increased incidence of venous thrombosis
among HT users.4-8 A meta-analysis performed by Meade9
showed a higher incidence of venous thrombosis with HT,
usually at the beginning of treatment. HT-triggered blood
clotting modifications that contribute to thrombosis are par-
ticularly important to identify in women with other throm-
botic risk factors, such as hereditary or acquired throm-
bophilia.10
Two large randomized prospective studies have refuted
observational studies that found cardioprotective effects
from hormone therapy. The Heart and Estrogen/Progestin
Replacement Study (HERS) was a randomized trial de-
signed to evaluate HT effects on the secondary prevention
of coronary heart disease. The results indicated that HT
enhanced coronary events within the first year of follow-
up after acute myocardial infarction (AMI) among patients
treated with a combination of conjugated estrogens/
medroxyprogesterone acetate at fixed doses, and a mean
age of 66.7 years.11 In addition, the Women’s Health Ini-
tiative (WHI) was interrupted early because of a higher in-
cidence of cardiovascular events in women using HT com-
pared to the placebo group.12 Recently, the results of the
therapeutic arm of the WHI, evaluating unopposed conju-
gated equine estrogens (CEE) versus placebo among 10,739
hysterectomized postmenopausal women, were published.
There was an increased risk of stroke (rr=1.39, 95% CI:
110-177), a decreased risk in hip fracture, and no effect
on the incidence of cardiovascular disease, as well as a po-
tential reduction in the incidence of breast cancer. Over-
all, the risk-benefit index was neutral.13
Results of the main randomized studies, HERS 2 and
WHI, indicate increased risk of venous thromboembolism
(VTE) with the use of HT.12,14 It is important to highlight
that these studies were criticized in at least two respects:
patient selection, which included women on average 10
years older than the age at which HT is usually recom-
mended (WHI), and the range of HR regimens used in both
studies, in terms of drugs, administration, and doses. Also,
the estrogen replacement and atherosclerosis (ERA) trial
randomly assigned more than 300 women with proven
coronary artery disease to estrogen, a combined estrogen-
progestin, or placebo. VTE, reported as an adverse effect,
was not significantly different among the groups.15 Rosano
et al (2003) suggested that hormone therapy had benefi-
cial cardiovascular effects in early postmenopausal women,
while it may have had detrimental effects on coagulative
balance and vascular inflammation.16
The administration route of HT appears to affect the fi-
brinolytic activity and the coagulation markers. Also, the
oral route is associated with changes in the levels of co-
agulation and fibrinolysis markers, especially during the
early period of use.17-19 Studies using the transdermal route,
however, did not confirm these findings.20-21 Moreover,
Scarabin et al. (2003),22 in a multicenter case-control study,
evaluated 155 postmenopausal women hospitalized because
of venous thromboembolism (VTE). They demonstrated an
increased risk for VTE with oral, but not transdermal,
therapy.23 Therefore, we decided to investigate the effect
of oral versus transdermal estrogen-progestin treatment on
AT-III levels in postmenopausal women, and compare them
to unopposed conjugated equine estrogen therapy. There is
a strong association between reduced levels of antithrombin
III and the development of thrombosis.24 This is thought
to be related to the anti-Xa activity.25 We also evaluated
the thrombin (F1+2 and TAT) generation markers, as well
as other coagulation parameters, such as prothrombin time,
partial activated thromboplastin time, thrombin time, fi-
brinogen, euglobulin lysis time, and platelet count, in post-
menopausal women after hormonal therapy, all important
parameters for analyzing the coagulation processes.
MATERIALS AND METHODS
A total of 45 postmenopausal women selected from the
Department of Gynecology of the Federal University of São
Paulo – Escola Paulista de Medicina were included in our
study (last natural menstruation at least 12 months prior
to entering the study, and FSH >40 mIU/mL, aged from
40 to 62 years, median = 54.6 years). In order to be in-
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cluded in this study, women could not have had uterine
bleeding or have used hormone therapy in the 180 days pre-
ceding admission to the study.
The following groups were deemed ineligible based on
the exclusion criteria: women with a body mass index e”
35; women who were taking vitamin supplements (vitamins
B6, B12 or folic acid), herbal substances, or phyto-
estrogens; those who practiced physical exercise (with the
exception of light walks less than three times a week); those
who had endometrial thickness > 5 mm according to ul-
trasonography carried out within the previous six months;
those who had any abnormality detected by recent mam-
mography or cervicovaginal oncological colpocytology
(carried out in the previous 12 months); and those who pre-
sented a personal history of cardiovascular disease or ve-
nous or arterial thromboembolism. Women presenting
dyslipidemia, diabetes mellitus, or acute or chronic hepat-
opathies were also excluded, as were those using choles-
terol-reducing medication, androgens, raloxifene,
tamoxifen, barbiturates, hydantoin, carbamazepine, phe-
nylbutazone, meprobamate, or rifampicin, and those with
hormone-dependent cancer. We also excluded patients us-
ing medication that could interfere with blood clotting. All
subjects voluntarily agreed to participate in the study, which
was approved by the institution’s Ethics Committee in Re-
search, and all patients gave their written informed con-
sent to participate in the study. Precocious menopause was
not included.
Patients were divided into three groups: A) oral conju-
gated equine estrogens (CEE), 0.625 mg/day (n = 15); B)
oral CEE, 0.625 mg/day, plus medroxyprogesterone (MP)
(n = 15); C) transdermal 17beta-estradiol, 50 µg/day, plus
MP (group C, N = 15). MP (5 mg/day) was given from the
first to the fourteenth day of each month. The patients in
the unopposed estrogen treatment were all hysterectomized.
Baseline blood values were obtained (T0), as were blood
values after three (T3), six (T6), and 12 (T12) months of hor-
mone treatment. Samples were also collected between the
12th and 14th day of each month of treatment (during the
MP treatment phase).
Plasma antithrombin III (AT-III) activity was measured
by a functional method (amidolytic procedure) using a
chromogenic substrate, in the presence of polybrene, as the
substrate for residual thrombin. p-Nitralinine (p-NA) re-
leased from the substrate H-D-Phe-Pip-Arg-p-NA was
measured photometrically at 405 nm using the end-point
procedure. The amount of thrombin inhibited by the anti-
thrombin III-heparin complex is proportional to the amount
of antithrombin III present.
Prothrombin time (PT), partial activated thromboplas-
tin time (APTT), and thrombin time (TT) were measured
in fresh citrated plasma by standard methods, and the re-
sults were expressed as the ratio of test sample/normal
plasma pool. Fibrinogen, as well as euglobulin lysis time
(ELT), was determined according to the method of Clauss,
using previously frozen plasma. ELISA assays were used
to measure fragment 1+2 (F1+2, Organon Teknika) and
thrombin-antithrombin III complex (TAT, Diagnostica
Stago).
Four patients left this study for either personal reasons
(n=1 from group A), abnormal bleeding (n=1 from group
B), nausea and headache (n=1 from group B), or breast pain
(n=1 from group C).
Statistical methods
An alpha error (P) of 0.05 was used. All values in the
figures and text are expressed as mean ± standard devia-
tion. All statistical tests were performed using GraphPad
Prism 3.00 for Windows (GraphPad Software, San Diego,
CA). The characteristic data of the groups was analyzed
by one-way repeated measures analysis of variance and
post-hoc Bonferroni tests. The number of patients per group
for a power calculation of 75% was 15 per group.
RESULTS
Figure 1 shows the values of antithrombin III levels dur-
ing this study. AT-III levels in patients of group B (oral CEE
plus MP) presented a reduction at T3 (92 ± 7%, p<0.05)
compared to baseline (pretreatment, 100 ± 5), T6 (104 ±
5), and T12 (100 ± 6). There were no AT-III level changes
in patients of group A (unopposed CEE) and group C
(transdermal 17beta-estradiol plus MP).
Figure 1 - Antithrombin III (AT-III) levels (mean ± standard error) during
one year of hormone therapy in patients receiveing oral CEE (group A),
oral CEE plus MP (group B), or transdermal 17β-estradiol plus MP (group
C). * = p < 0.05, compared to initial values.
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Table 1 summarizes the values of the coagulation pa-
rameters analyzed in this study. F1+2 increased in all pa-
tients after three months of treatment (0.20 ± 0.25, 0.26 ±
0.15, and 0.27 ± 0.14, for groups A, B and C, respectively),
but it reached statistical significance only in group C (0.10
± 0.19 and 0.27 ± 0.14, for baseline and T3, respectively,
p<0.05). TAT levels decreased at T3 in all groups (13.7 ±
3.2, 13.1 ± 4.6, and 15.1 ± 0.14, for groups A, B and C,
respectively), but this reduction was only significant in
group B (16.1 ± 3.9 and 13.1 ± 4.6, baseline and T3, re-
spectively, p<0.05). Fibrinogen levels were significantly
higher at T12 in groups B (3.9 ± 0.8) and C (4.3 ± 2.0) com-
pared to their respective baselines (3.0 ± 0.5 and 2.8 ± 0.5,
groups B and C, respectively, p<0.05).
Table 2 shows the values of PT, APTT, TT, platelet
count, and ELT during this study. PT was shortened in all
patients from T3 through T12 compared to baseline in each
group (p<0.05). APTT, TT, platelet count, and ELT were
not modified during treatment in any group.
DISCUSSION
The hypercoagulability state is a condition that may in-
duce the thrombosis phenomenon. In our study, the mark-
ers of this state were identified in patients who received
estrogen associated with progestagens. Furthermore, the
group that received oral estrogen plus medroxiprogesterone
showed a decrease in antithrombin III, which is a risk fac-
tor for thrombosis. Therefore, our results suggest that this
(these) association(s) lead to a procoagulant state.
In a previous study, we observed AT-III reduction in pa-
tients receiving oral CEE plus MP, and no AT-III change
in patients taking transdermal 17beta-estradiol and MP.26
These results are confirmed by the current study; the AT-
III levels decreased only in women taking oral CEE plus
MP, and they were not changed by a transdermal 17beta-
estradiol plus MP regimen. It is interesting to note that this
effect on AT-III disappeared when oral CEE was used with-
out MP in the present study.
Oral CEE caused AT-III reduction in some studies on
the effect of short- and long-term hormone therapy.27-30
Some authors observed AT-III reduction with ethinyl
estradiol31-33 and with estradiol valerate.32,33 On the other
hand, AT-III reduction during HT with oral CEE was not
observed by others, but this may be due to methodology.
For example, the Gilabert34 conducted a transversal study
where AT-III was measured only once, and Elzelsberger et
al.35 measured AT-III levels by an immunological method.
In our prospective study, patients were observed for one
year and differences were detected in relation to initial val-
ues. The study design or the method used for AT-III deter-
mination can account for these discrepancies.
As in our previous study,26 we did not observe AT re-
Table 1 - Results (mean ± standard deviation) of AT, F1+2,
TAT, and fibrinogen determinations during one year of
hormone replacement therapy (T0 through T12) in patients
receiveing oral CEE (group A), oral CEE plus MP (group
B), or transdermal 17β-estradiol plus MP (group C).
T0 T3 T6 T12
Group A
AT-III (%) 102 ± 5 101 ± 7 105 ± 8 100 ± 8
F 1+2 (nmol/l) 0.12 ± 0.1 0.20 ± 0.25 0.20 ± 0.12 0.35 ± 0.3
TAT (ng/ml) 16.2 ± 4.3 13.7 ± 3.2 14.8 ± 4.3 15.5 ± 3.9
Fibrinogen (g/l) 3.3 ± 0.7 3.1 ± 0.5 3.2 ± 0.6 3.9 ± 1.5
Group B
AT-III (%) 100 ± 5 92 ± 7 * 104 ± 5 100 ± 6
F 1+2 (nmol/l) 0.14 ± 0.14 0.26 ± 0.15 0.18 ± 0.12 0.24 ± 0.16
TAT (ng/ml) 16.1 ± 3.9 13.1 ± 4.6 * 15.6 ± 2.7 15.9 ± 3.1
Fibrinogen (g/l) 3.0 ± 0.5 2.7 ± 0.5 2.9 ± 0.7 3.9 ± 0.8 *
Group C
AT-III (%) 95 ± 9 94 ± 7 100 ± 9 97 ± 6
F 1+2 (nmol/l) 0.10 ± 0.19 0.27 ± 0.14 * 0.15 ± 0.26 0.11 ± 0.16
TAT (ng/ml) 18.1 ± 8.2 15.1 ± 4.0 16.5 ± 3.5 15.8 ± 4,1
Fibrinogen (g/l) 2.8 ± 0.5 2.9 ± 0.4 2.8 ± 0.6 4.3 ± 2.0 *
* p < 0.05, compared to initial values. The normality rates for each test: AT-
III (antithrombin III) – 70 to 120%; F 1+2 (fragment 1 + 2) < 1.1 nmol “ L;
TAT (thrombin-antithrombin III complex) – 10 to 41 ng/mL; fibrinogen 2
to 4 g/L.
Table 2 - Results (mean ± standard deviation) of PT, APTT,
TT, platelet count, and euglobulin lysis time during one year
of hormone therapy in patients receiveing oral CEE (group
A), oral CEE plus MP (group B), or transdermal 17β-
estradiol plus MP (group C).
T0 T3 T6 T12
Group A
PT (ratio) 1.14 ± 0.09 0.97 ± 0.04 * 0.97 ± 0.04 * 1.01 ± 0.04 *
APTT (ratio) 0.92 ± 0.2 0.91 ± 0.1 1.03 ± 0.1 1.01 ± 0.1
TT (ratio) 1.08 ± 0.1 1.08 ± 0.1 1.09 ± 0.1 1.07 ± 0.1
Platelets ´ 103/?l 193 ± 49 196 ± 47 215 ± 105 221 ± 67
ELT (hours) 5.6 ± 0.5 5.0 ± 0.7 5.3 ± 0.7 5.6 ± 0.8
Group B
PT (ratio) 1.21 ± 0.10 0.98 ± 0.10 * 0.96 ± 0.06 * 1.00 ± 0.04 *
APTT (ratio) 1.05 ± 0.1 1.02 ± 0.1 1.11 ± 0.2 1.05 ± 0.1
TT (ratio) 1.10 ± 0.1 1.06 ± 0.1 1.07 ± 0.1 1.13 ± 0.1
Platelets × 103/µL 173 ± 34 183 ± 29 187 ± 36 203 ± 50
ELT (hours) 5.7 ± 0.5 5.2 ± 0.8 5.4 ± 0.7 5.8 ± 0.5
Group C
PT (ratio) 1.06 ± 0.12 0.96 ± 0.07 * 1.02 ± 0.06 * 1.01 ± 0.06 *
APTT (ratio) 1.06 ± 0.2 1.17 ± 0.1 1.14 ± 0.1 1.07 ± 0.1
TT (ratio) 1.08 ± 0.1 1.06 ± 0.1 1.06 ± 0.1 1.09 ± 0.1
Platelets × 103/µL 185 ± 32 245 ± 26 255 ± 26 196 ± 59
ELT (hours) 5.6 ± 0.7 5.4 ± 0.9 5.4 ± 0.9 5.5 ± 0.8
 * p < 0.05, compared to initial values. The normality rates for each test: PT
(prothrombin time) 0.85 to 1.20; APTT (partial activated thromboplastin
time – 0.80 to 1.25; TT < 1.20; platelets 150.000 to 400.000/m3; ELT
(euglobulin lysis time) > 5 hours.
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duction in patients taking transdermal 17beta-estradiol plus
MP. This data suggests that oral estrogen decreases AT-III
levels, an effect that is not observed with transdermal ad-
ministration, avoiding the first-pass effects of intestinal and
hepatic metabolism. Sporrong36 observed an AT-III level
decrease in patients taking transdermal 17beta-estradiol, but
only in those who used larger prostagen doses, suggesting
that progestagens, rather than estrogens alone, may be re-
sponsible for these changes in hemostasis.
F1+2 and TAT complex are sensitive markers for acti-
vation of blood coagulation.37-39 Monitoring these markers
can identify a hypercoagulable state associated with a sta-
tistically significant reduction of AT-III levels, despite re-
maining within the normal range (higher than 70%). F1+2
levels increased after three months of treatment in all the
groups, compared to the initial values. They reached sta-
tistical significance only in patients receiving transdermal
17beta-estradiol plus MP at T3; that is, in patients with no
AT-III reduction. This is in contrast with the findings of
Kroon27 and Caine,29 who observed high F1+2 levels in
women receiving oral CEE, though this phenomenon was
not seen in those receiving transdermal 17beta-estradiol.
As we observed for AT-III and F1+2 levels, they were al-
ways within the normal range, suggesting that the eleva-
tion is not clinically relevant.
There was a TAT complex reduction in all of the groups
at T3, but it was significant only in the women taking oral
CEE associated with MP (group B), the same patients who
showed a significant AT reduction. This is an intriguing
finding, which was also observed by Kroon27 in patients re-
ceiving oral CEE. In spite of having high F1+2 levels, sug-
gesting a hypercoagulable state, patients had a lower pro-
duction of the TAT complex. Perhaps the reduction of AT-
III levels could have contributed to this fact. Other authors
did not observe an increase of F1+2 or TAT in users of oral
CEE or transdermal 17beta-estradiol.40-41
The shortening of PT observed in all groups could be
related to the increase in factor VII. Meade42 observed a
PT reduction, and Lindberg33 found higher factor VII lev-
els in women on HRT. APTT and TT did not change in
this or other studies.35,36,42
Fibrinogen levels increased at T12 in patients receiving
MP associated with either oral CEE or transdermal 17beta-
estradiol. In fact, estrogens seem to reduce fibrinogen lev-
els, a fact which is reverted by progestagen, as observed
here and in other studies.41,43-45
As in our previous study,26 we did not detect changes
in fibrinolytic activity, as evaluated by the euglobulin lysis
time. Reduced PAI-1 levels and higher t-PA levels after
HRT have been reported, which can increase the fibrino-
lytic potential in these patients.46-48
These results confirm that oral CEE plus MP can re-
duce AT-III levels, as we observed previously, whereas un-
opposed CEE or transdermal 17beta-estradiol associated
with MP did not change AT-III levels. There is no evidence
of activation of blood coagulation, since the AT-III level
was not reduced below normal range, and the F1+2 eleva-
tion was only modest. We believe that these changes are
not clinically relevant when the general population is con-
sidered. However, more studies are necessary to evaluate
the impact of postmenopausal hormone therapy in women
with other risk factors for thrombosis, such as congenital
or acquired thrombophilia.
Also, the disturbances in the endothelial function play
an important role in the pathophysiology of cardiovascu-
lar disease, and several lines of evidence suggest that in-
terventions in the endothelial function could modify the
progression of cardiovascular risk factors. Therefore, fur-
ther studies are needed to test the impact of hormone
therapy on the endothelial function, using inflammatory
markers such as decreased expression of adhesion mol-
ecules (e.g., ICAM-1, VICAM-1 and E-selectin or C-reac-
tive protein49-53), fibrinolytic/thrombogenic markers54,55 and
functional methods (e.g., ultrasonography of the brachial
artery and plasma nitrite/nitrate level measurements) to de-
termine the real risk of hormone therapy on postmenopau-
sal cardiovascular disease.
RESUMO
Bonduki CE, Lourenço DM, Motta ELA, Soares Jr. JM,
Haidar MA, Baracat EC. Efeitos da terapia de reposição
hormonal estroprogestativa sobre o sistema de coagulação
e de fibrinólise em mulheres na pós-menopausa.Clinics.
2007;62(5):553-60.
OBJETIVO: Avaliar os marcadores antitrombina III (AT),
fragmento 1 + 2 da trombina (F1+2) e complexo trombina-
antitrombina (TAT), bem como outros parâmetros da coa-
gulação, como tempo de pró-trombina, tempo parcial de
tromboplastina ativado, tempo de trombina, fibrinogênio e
tempo de lise da euglobulina em mulheres na pós-meno-
pausa após terapia hormonal.
DESENHO DO ESTUDO: Foram incluídas 45 voluntári-
as que receberam estrogênios conjugados eqüinos (ECE)
0,625 mg/dia, isoladamente ou associado ao acetato de
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medroxiprogesterona (AMP) ou usaram o 17beta-estradiol
(50 µg/dia) transdérmico com AMP. Os exames foram rea-
lizados antes do tratamento (T0) e após três (T3), seis (T6)
e doze (T12) meses após o início do tratamento. AT foi ava-
liada pelo método amidolítico, enquanto que o F1+2 e o
complexo TAT por ELISA.
RESULTADOS: Houve redução significante nos níveis de
AT em pacientes que receberam ECE associado ao AMP
no T3. Não houve redução na AT em mulheres que usa-
ram ECE isoladamente ou aquelas com 17beta-estradiol
transdérmico e AMP. O F1+2 aumentou em todos os gru-
pos, mas apenas o grupo com 17beta-estradiol transdérmico
e AMP apresentou diferença significante durante o T3.
CONCLUSÕES: A associação de ECE e AMP pode redu-
zir os níveis de AT, enquanto ECE isoladamente ou 17beta-
estradiol transdérmico com AMP não modificam-o acentu-
adamente. Essas alterações poderiam ser mais relevantes cli-
nicamente na análise populacional. Todavia, a terapia de re-
posição hormonal aumentaria o risco de trombose em mu-
lheres com trombofilia prévia congênita ou adquirida.
UNITERMOS: Antitrombina III. Terapia hormonal da pós-
menopausa. Estrogênio. Menopausa. Tromboembolismo.
Gerador de trombina.
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